Product
Patients and health care professionals appreciate that NightWare is easy to use.
nightware.comCrawled Oct 15, 2026
Patients and health care professionals appreciate that NightWare is easy to use.
NightWare Announces Leadership Transition and Strategic Investment Plan
The company was inspired by Tyler’s efforts to help his father, who experienced PTSD-related nightmares after military service. Tyler developed a prototype device to help his father and others with nightmares.
The company provides a webform for inquiries about recommending NightWare, advocating for access, receiving company updates, or making an investment.
NightWare is a prescription digital therapeutic system for reducing sleep disturbance related to Nightmare Disorder or PTSD-related nightmares. It is FDA-cleared and improves sleep in adults 22 and older with these conditions.
San Francisco first responders experience fewer nightmares and reduced distress after using a prescription wearable device over 60 days. The pilot study targets PTSD-related nightmares, which impair sleep and elevate suicide risk among trauma-exposed professionals. Researchers observe real-world improvements in sleep quality and emotional well-being through the device’s intervention.
EXIT 156 Capital invests in Nightware, a digital therapeutic company, to expand treatment for PTSD-related nightmare disorder. The partnership targets deployment across the U.S. Department of Veterans Affairs (VA) system. Nightware’s FDA-cleared solution delivers evidence-based interventions via mobile platforms.
NightWare introduces a new leadership transition and outlines a strategic investment plan. The company aims to strengthen its position in sleep technology by securing additional funding and refining its product roadmap. Key initiatives focus on expanding research and development to enhance sleep-tracking accuracy and user experience.
NightWare, a digital therapeutic system, helps veterans manage PTSD-related nightmares using Apple Watch and iPhone. The solution integrates with Apple’s ecosystem to provide targeted interventions during sleep disturbances. Studies highlight its potential to reduce the frequency and intensity of nightmares for affected individuals.
Tyler Skluzacek developed a smartwatch app targeting PTSD-related nightmares after his father, Patrick, struggled with severe sleep disturbances. The app delivers gentle vibrations to interrupt nightmares during sleep. It has now received FDA approval for use.
NightWare receives FDA clearance to market a digital therapeutic device that uses an Apple Watch to interrupt PTSD-related nightmares through vibrations. The system aims to prevent distressing dream sequences by delivering subtle alerts during sleep.
A prescription smartwatch app helps patients with nightmare disorders monitor and potentially reduce nightmares. The tool integrates with wearable technology to track sleep patterns and provide real-time feedback. Early findings suggest it may improve sleep quality for users struggling with recurrent nightmares.
NIGHTWARE’s digital therapeutic app receives authorization for temporarily reducing sleep disturbances caused by nightmares in adults aged 22 and older with PTSD. The FDA also approves INMAZEB for Ebola treatment, REACTIV8’s implantable neurostimulation system for chronic pain management, and proposes withdrawing MAKENA (hydroxyprogesterone caproate) from the market.
The FDA approves **NightWare**, a mobile app designed to reduce nightmares in adults with nightmare disorder or PTSD-related nightmares. The app targets sleep disturbances by intervening during REM sleep cycles. NightWare is the first digital health tool of its kind cleared for this specific use by the FDA.